Clinical Trial Update: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of HBI-2438 in KRAS G12C-mutant solid tumors; the trial is active but not recruiting and targets indications including non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• HBI-2438

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Lung Cancer, Non Small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING